

# Supplementary material

## Network-Based Prediction of Side Effects of Repurposed Antihypertensive Sartans against COVID-19 via Proteome and Drug-Target Interactomes

Despoina P. Kiouri <sup>1,2,†</sup>, Charalampos Ntallis <sup>1,†</sup>, Konstantinos Kelaidonis <sup>3</sup>, Massimiliano Peana <sup>4</sup>, Sotirios Tsiodras <sup>5</sup>, Thomas Mavromoustakos <sup>2</sup>, Alessandro Giuliani <sup>6</sup>, Harry Ridgway <sup>7,8</sup>, Graham J. Moore <sup>9,10</sup>, John M. Matsoukas <sup>3,10,11,12,\*</sup>, and Christos T. Chasapis <sup>1,\*</sup>

<sup>1</sup> Institute of Chemical Biology, National Hellenic Research Foundation, 11635 Athens, Greece; despoina.kiouri.99@gmail.com (D.P.K.); xntallis@gmail.com (C.N.)

<sup>2</sup> Department of Chemistry, Laboratory of Organic Chemistry, National Kapodistrian University of Athens, 15772 Athens, Greece; tmavrom@chem.uoa.gr

<sup>3</sup> NewDrug PC, Patras Science Park, 26504 Patras, Greece; k.kelaidonis@gmail.com

<sup>4</sup> Department of Chemical, Physical, Mathematical and Natural Sciences, University of Sassari, Via Vienna 2, 07100 Sassari, Italy; peana@uniss.it

<sup>5</sup> 4th Department of Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece; sotirios.tsiodras@gmail.com

<sup>6</sup> Environment and Health Department, Istituto Superiore di Sanità, 00161 Rome, Italy; alessandro.giuliani@iss.it

<sup>7</sup> Institute for Sustainable Industries and Liveable Cities, Victoria University, Melbourne, VIC 8001, Australia; ridgway@vtc.net

<sup>8</sup> AquaMem Consultants, Rodeo, NM 88056, USA

<sup>9</sup> Pepmetics Inc., 772 Murphy Place, Victoria, BC V6Y 3H4, Canada; mooregj@shaw.ca

<sup>10</sup> Department of Physiology and Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada

<sup>11</sup> Institute for Health and Sport, Victoria University, Melbourne, VIC 3030, Australia

<sup>12</sup> Department of Chemistry, University of Patras, 26504 Patras, Greece

\* Correspondence: imats1953@gmail.com (J.M.M.); cchasapis@eie.gr (C.T.C.)

† These authors contributed equally to this work.

## Supplementary excel files table of contents:

### 1. Allelic\_variants\_Protein\_Targets\_OMIM.....

Sheet1: AGTR1\_allelic\_variants .....

Sheet2: PPARG\_allelic\_variants .....

### 2. Alternative\_transcription\_variants.....

Sheet1: AGTR1 .....

Sheet2: PPARG .....

Sheet3: ACE2 .....

Sheet4: NR1I2 .....

### 3. Gene\_Disease\_First\_Neighbors\_Sartans\_Paxlovid.....

Sheet1: AGTR1\_JUN\_PPARG .....

Sheet2: AGTR1 .....

Sheet3: NR1I2 .....

Sheet4 ACE2 .....

### 4. Gene\_Disease\_Targets\_Sartans\_Paxlovid.....

Sheet1: AGTR1 .....

Sheet2: JUN .....

Sheet3: PPARG .....

Sheet4: NR1I2 .....

Sheet5: ACE2 .....

### 5. Drug\_Targets\_ALL\_Drugs\_DrugBank .....

Sheet1: Sartans .....

Sheet2: Paxlovid .....

### 6. Post\_Translational\_Modifications\_Uniprot.....

Sheet1: Targets .....

Sheet2: ACE2\_ALL\_FN .....

Sheet3: ACE2\_Top10ConnectedFN .....

Sheet4: AGTR1\_ALL\_FN .....

Sheet5: AGTR1\_Top10ConnectedFN .....

Sheet6: NR1I2\_ALL\_FN .....

Sheet7: NR1I2\_Top10ConnectedFN .....

### 7. Gene\_Ontology\_BiNGO

Sheet1: Targets .....

## 8. Gene\_Ontology\_Panther

Sheet1: Sartans\_First\_Neighbors.....

Sheet2: Paxlovid\_First\_Neighbors.....

Sheet3: AGTR1\_First\_Neighbors .....

Sheet4: ACE2\_First\_Neighbors .....

## 9. ALL\_Network\_Analysis

Sheet1: Sartans\_network .....

Sheet2: Irbesartan\_network .....

Sheet3: Telmisartan\_network .....

Sheet4: Sartans\_COVID.....

Sheet5: Ritonavir (Paxlovid) .....

## 10. Structural\_simillarity\_Tanimoto

Sheet1: Ritonavir .....

Sheet2: Nirmatrelvir.....